Asst Di Mantova
- Address
- lock Available on a paid plan
Respiratory Diseases and Oncology
At Asst Di Mantova, clinical research in Respiratory Tract Diseases and Neoplasms focuses on improving care for people with asthma and lung cancer. These studies are designed to test new treatments, compare them with current options, and better understand how to control symptoms and slow disease progression.
- Severe asthma with an eosinophilic phenotype
- Inadequately controlled asthma
- Non-small cell lung cancer and small cell lung cancer
The site is contributing to research that evaluates treatment effectiveness, supports better lung function, and explores new approaches for advanced lung cancer.
Severe Asthma and Allergic Skin Disease
Research in Skin and Connective Tissue Diseases and Respiratory Tract Diseases includes studies for chronic spontaneous urticaria and difficult-to-control asthma. The goal is to assess whether emerging therapies can reduce itching, hives, and airway symptoms more effectively than existing care.
- Chronic spontaneous urticaria
- Inadequately controlled asthma
- Severe asthma with an eosinophilic phenotype
These trials help clarify how new treatments may improve day-to-day disease control and quality of life for patients with long-term inflammatory conditions.
Lung Cancer Research
The oncology program at this hospital includes studies in non-small cell lung cancer and small cell lung cancer, with a strong focus on advanced disease. The research is aimed at comparing treatment strategies, improving survival outcomes, and identifying better ways to manage cancer that has returned or progressed.
- Metastatic non-small cell lung cancer
- Non-small cell lung cancer
- Small cell lung cancer
By studying both immunotherapy-based and chemotherapy-based approaches, the site is helping to refine how lung cancer is treated in real-world clinical settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Asst Di Mantova
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Assessment of Efficacy and Safety of Budesonide and Formoterol Fumarate Inhalation in Patients with Inadequately Controlled Asthma | AstraZeneca AB | Phase III | Not Recruiting | Mar 2022 | Feb 2025 |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 2 | Unknown | 2024-09-10 | 2024-09-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.